Cumberland Pharmaceuticals vs Pelthos Therapeutics
Cumberland Pharmaceuticals is the larger business, with $44.5m of revenue in fiscal 2025 against $16.8m for Pelthos Therapeutics (2.7 times as much). Cumberland Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -6.4% against -257.9%. Cumberland Pharmaceuticals carries less debt relative to equity (21.1% against 80.9%).
| Latest fiscal year | Cumberland PharmaceuticalsCPIX, 2025 | Pelthos TherapeuticsPTHS, 2025 |
|---|---|---|
| Revenue | $44.5m | $16.8m |
| Revenue growth | 17.6% | — |
| Net income | −$2.8m | −$43.3m |
| Operating margin | -6.3% | -193.1% |
| Net margin | -6.4% | -257.9% |
| Return on equity | -11.9% | — |
| Free cash flow | $4.8m | −$22.7m |
| Cash | $11.4m | $18.0m |
| Total debt | $5.2m | $31.4m |
| Debt to equity | 21.1% | 80.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $263,478 | $0 |
| Employees | 93 | 92 |
| Market value | $64.4m | $39.1m |
| Price vs our value range | Above our value range | — |
| Moat score | 57 (Moderate) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 24 sales |